Sun exposure, smoking history, and genetics all move that needle too
Semaglutide- and tirzepatide-class medications carry real, documented risks discussed in the safety section above
Semaglutide has been used for diabetes management for years, with no emerging safety signals in long-term follow-up
GIP affects the ability of the body to expand its white adipose tissue storage in a healthy way allowing for increased lipid breakdown and decreased lipid spillover and ectopic fat accumulation in various organs [13]
For labs building comparative datasets between triagonist and dual agonist compounds, this difference is not academic it is the entire point of the study
These medications are usually taken as weekly injectables, but Rybelsus and more recently, Wegovy is available as a once-daily pill